MacroGenics, Inc. (NASDAQ: MGNX) today announced positive results from SOPHIA, the Company’s Phase 3 clinical study of margetuximab in HER2-positive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

MacroGenics (MGNX) PT Raised to $40 at SunTrust Robinson HumphreyFebruary 6, 2019 1:30 PM Macrogenics (MGNX) Adds to Gains, Up 140%February 6, 2019 9:06 AM Macrogenics (MGNX) Could Trade to $2B+ Valuation - Evercore ISIFebruary 6, 2019 8:47 AM Macrogenics (MGNX) Climbs 100% After Reporting Positive Results from Pivotal Phase 3 SOPHIA Study of MargetuximabFebruary 6, 2019 7:55 AM MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of MargetuximabFebruary 6, 2019 6:00 AM Pre-Open Stock Movers 02/04: (MXWL) (ULTI) (EOLS) Higher; (MGNX) (MTCH) (PEGI) Lower (more...)February 4, 2019 9:25 AM Citi Downgrades MacroGenics (MGNX) to SellFebruary 4, 2019 4:07 AM